Esperion Therapeutics (ESPR) Other Working Capital Changes (2012 - 2026)

Esperion Therapeutics has reported Other Working Capital Changes for 15 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 83.84% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (up 872.85% YoY), and the FY2025 full-year result was $8.7 million, changed N/A from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $9.1 million, up from -$13.4 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $14.7 million in Q3 2025, with the low at -$13.7 million in Q3 2023.
• Historically, Other Working Capital Changes has averaged $517117.6 across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 884.02% — and 2023, when it soared 631.65%.
• Esperion Therapeutics' Other Working Capital Changes stood at -$1.9 million in 2022, then slumped by 142.85% to -$4.6 million in 2023, then surged by 322.69% to $10.3 million in 2024, then tumbled by 230.01% to -$13.4 million in 2025, then soared by 167.46% to $9.1 million in 2026.
• The last three Other Working Capital Changes figures came in at $9.1 million (Q1 2026), -$13.4 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.